Connection

DAVID LONARD to MCF-7 Cells

This is a "connection" page, showing publications DAVID LONARD has written about MCF-7 Cells.
Connection Strength

0.519
  1. A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells. Commun Biol. 2021 03 25; 4(1):399.
    View in: PubMed
    Score: 0.174
  2. Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination. Sci Rep. 2019 10 22; 9(1):15099.
    View in: PubMed
    Score: 0.158
  3. Proteomic profiling identifies key coactivators utilized by mutant ERa proteins as potential new therapeutic targets. Oncogene. 2018 08; 37(33):4581-4598.
    View in: PubMed
    Score: 0.036
  4. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat Commun. 2018 03 28; 9(1):1270.
    View in: PubMed
    Score: 0.035
  5. Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells. Cancer Res. 2017 08 15; 77(16):4293-4304.
    View in: PubMed
    Score: 0.034
  6. Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death. Cancer Cell. 2015 Aug 10; 28(2):240-52.
    View in: PubMed
    Score: 0.030
  7. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014 Mar 01; 74(5):1506-1517.
    View in: PubMed
    Score: 0.026
  8. Proteomic analysis of coregulators bound to ERa on DNA and nucleosomes reveals coregulator dynamics. Mol Cell. 2013 Jul 25; 51(2):185-99.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.